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Abstract 
Background: The effects of psychotropic drugs on cardiac repolarization have increasingly 
gained attention in research and clinical practice over the last 2 decades. The absolute risk of 
cardiac arrhythmia, such as the polymorphic ventricular tachycardia, Torsades de Pointes (TdP), 
is low (14 per 10,000 patients/year) and sudden cardiac death as a consequence of all cardiac 
arrhythmias is less frequent (Braillon et al., 2017). TdP can occur at therapeutic doses of second-
generation antipsychotics and antidepressants and with a corrected Q-T (QTc) interval >500 ms. 
Many psychotropic medications can delay cardiac repolarization thereby producing prolonged 
QTc in the electrocardiogram (ECG). Emergency departments (EDs) are a frequent point of care 
for patients diagnosed with psychiatric medical disorders taking one or more psychotropic 
medications.  
Purpose of Project: Using evidence-based practice, this project standardize the cardiac 
assessment of psychiatric patients in the ED who were on one or more psychotropic medications 
by performing a 12-lead ECG on arrival to rule out QTc prolongation, thus reducing the risk of 
polymorphic ventricular tachyarrhythmia.  
Outcomes: Fifty patient-ECGs were evaluated and compared by psychotropic medication; all 
were within normal range. Recommend continuance of ECG protocol to assess for the possibility 
of QTc prolongation and to prevent its progression to TdP. 
 Keywords: Psychotropic medications, psychiatric medications, QT prolongation, QTc 
prolongation, 12-lead ECG, emergency department, Torsades de Pointes. 
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Impact of Psychotropic Medications on Electrical Cardiac 
Conduction in the Emergency Department: A Best Practice Review 
Description of the Clinical Problem 
The effect of psychotropic drugs on cardiac repolarization has increasingly gained 
attention in research and clinical practice over the last two decades. A prolonged QTc may in 
rare cases contribute to TdP emergence and, while often self-limited, could progress to 
ventricular fibrillation and sudden cardiac death. Of the psychotropic drugs, antipsychotics and 
some antidepressants have both been proven to increase QTc and are associated with TdP and 
sudden cardiac death. 
Prior to a drug’s approval, the U.S. Food and Drug Administration (FDA) requires 
manufacturers to perform comprehensive investigations on the medication side-effects profile to 
include evaluation of QT and QTc prolongation risks. The most commonly known drug-induced 
mechanism of QT prolongation occurs when the inward rectifier potassium (I Kr) channel of 
cardiomyocytes is inhibited, thus resulting in delayed cardiac action potential. First generation 
antipsychotics (i.e., dopamine antagonists, neuroleptics) were primarily used to treat 
schizophrenia and other psychotic disorders, as well as thioridazine (Mellaril, Mellaril-S), 
pimozide (Orap), and haloperidol (Haldol, Haldol Decanoate, Peridol) have all been found to 
prolong the QTc. Selective serotonin reuptake inhibitors (SSRIs) have been controversial in their 
effects on the QTc, leading the FDA to perform random crossover studies to compare the effects 
of citalopram (Celexa) to its S-isomer escitalopram (Cipralex, Lexapro), as well as to sertraline 
(Zoloft). Results of these case studies indicated that fluoxetine (Prozac) could protect against 
post-MI cardiovascular events including arrhythmias. Women demonstrated a significantly more 
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pronounced prolongation in the QTc interval than men; however, men typically had a longer 
QTc.  
TdP is a potentially dangerous side effect of several psychotropic medications but is 
difficult to study because of its low rate of occurrence. The absolute risk of cardiac arrhythmia, 
such as Torsades de Pointes (TdP) is low (14 per 10,000 patients) annually, while sudden cardiac 
death as a consequence of all cardiac arrhythmias occurs even less frequently (Braillon et al., 
2017). TdP can occur at therapeutic doses of second-generation antipsychotics and 
antidepressants and with a corrected QT (QTc) interval >500 ms. Many psychotropic 
medications can delay cardiac repolarization, thereby producing a prolonged QTc in the 
electrocardiogram (ECG). In rare cases, a prolonged QTc may cause life-threatening 
polymorphic ventricular tachyarrhythmia such as TdP. TdP is often self-limited but may lead to 
ventricular fibrillation and sudden cardiac death.  
The QT interval is a measure of combined cardiac depolarization and repolarization 
(Postema & Wilde, 2014). The QT interval starts with the beginning of the QRS-complex (i.e., 
ventricular depolarization) and ends with termination of the T-wave (i.e., ventricular 
repolarization). QTc prolongation is defined as > 450 ms for men and > 470 ms for women 
(Goldenberg et al, 2013). In healthy adults, a mean QTc prolongation of > 5 ms due to 
medication is cause for concern in toxicity studies (Hasnain & Vieweg, 2014). Proven to prolong 
QTc and associated with TdP and sudden cardiac death are psychotropic drugs, antipsychotics, 
and some antidepressants. These antidepressants include the classes of conventional 
antipsychotics, dopamine stabilizers, serotonin antagonist/reuptake inhibitors, noradrenergic and 
specific serotonergic antidepressants, norepinephrine and dopamine reuptake inhibitors, selective 
norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, serotonin-dopamine 
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antagonists, serotonin and norepinephrine reuptake inhibitors, serotonin 1A partial agonists, 
serotonin partial agonist reuptake inhibitors, and tricyclic/tetracyclic antidepressants. The 
emergency department (ED) frequently serves as a point of care for patients diagnosed with 
psychiatric medical disorders taking prescribed psychotropic medications. 
Numerous study designs, to include meta-analyses, systematic reviews, randomized 
controlled studies, case-control and cross-sectional studies, have justified concerns regarding the 
risk of prolonged QTc, prompting regulatory agencies such as the USA Federal Drug 
Administration (FDA) to investigate this side effect of prescribed medications to monitor their 
safety. Several factors are considered when analyzing the effect of QTc prolongation, including 
age (< or > 60 years); sex; metabolic inhibition of another drug (e.g., CYP2C19 inhibitors) or 
those of who are poor CYP2C19 metabolizers; hepatic impairment; concurrent use of another 
QTc-prolonging drug (Hasnain et al, 2013); cardiac disease (e.g., congestive heart failure), 
cardiac structural or electrical abnormalities or coronary heart disease; congenital long QT 
syndrome (Arizona University-based Center for Education and Research on Therapeutics 
[AZCERT],n.d.), hypomagnesemia; and hypokalemia. AZCERT’s CredibleMeds website was 
accessed to identify second- generation antidepressants (SGAD) and second-generation 
antipsychotics (SGAP) medications. Attention was focused on psychotropic medications that 
caused prolongation of the QT/QTc interval and sudden cardiac death; seven SGADs (i.e., 
citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, venlafaxine) and nine 
SGAPs (i.e., amisulpride, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, 
risperidone, sertindole, ziprasidone. Haloperidol (Haldol) is a common first-generation 
antipsychotic (FGAP) in use that has been found to potentiate QTc prolongation.  
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The American Heart Association (AHA) and the American College of Cardiology 
Foundation (ACCF) released a scientific statement to raise awareness among health care 
professionals about the risk, ECG monitoring, and management of drug-induced QT interval 
prolongation and TdP in hospitalized patients. This statement emphasized the importance of 
awareness of risk factors in order to minimize the likelihood of occurrence of drug-induced TdP 
(Drew et al., 2010). In a 5-year cross-sectional ECG screening in 6,790 adult psychiatric 
inpatients, 27.3% had abnormal ECGs, 1.6% had long QT, and 0.95% qualified as drug-induced 
long QT case subjects. Sudden cardiac death was recorded in five patients and TdP was recorded 
in seven other patients (Girardin et al., 2013).  
Currently, there is a paucity of national or international guidelines or consensus 
documents with specific recommendations regarding ECG monitoring and screening for 
antidepressant and antipsychotic treatment. Existing guidance typically recommends ECG 
monitoring and screening before and during the start of psychotropic medicines known to cause 
QTc prolongation in those vulnerable to CYP2C19 inhibitors or metabolizers. The Food and 
Drug Administration (FDA, 2012) issued a warning about the SGAD citalopram (Celexa) and its 
potential risk for QTc prolongation leading to TdP at doses greater than 40 mg orally. Newer 
product labeling urged providers to use lower doses, to not exceed 20 mg in patients older than 
60 years of age, in patients with hepatic dysfunction, those who were poor CYP219 
metabolizers, and those taking concomitant CYP2C19 inhibitors. Due to this warning, the 
maximum dose of citalopram changed to 40 mg daily in nonelderly persons (Forest 
Pharmaceuticals, Inc, 2012). Antidepressant use has increased in 2017-2018 from 10.6% to 
13.8% in the United States (Brody & Gu, 2020). More than 34.4 million adults took 
antidepressants in 2014, up from 13.4 million in 2010, and over 242 million U.S. adults filled 
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one or more prescriptions for psychiatric medications (Moore & Mattison, 2017). With the 
SARS-CoV-2 pandemic, mental health demand has increased in the United States by over 40.9% 
during the month of June 2020, when compared to June 2019. The impact of stay-at-home 
orders, social distancing, loss of employment and wages, and stresses on care providers and 
loved ones have contributed to a 30.9% increase in reported symptoms of anxiety and depressive 
disorders, a 26.3% increase in trauma or stressor-related disorders, a 13.3%, increase in 
substance use to cope with the stress or emotions related to SARS-CoV-2, and a 10.7% increase 
in the admitted incidence of suicidal ideations (Czeisler et al, 2020). 
According to the Centers for Disease Control and Prevention (CDC, n.d.), an estimated 
50% of Americans will be diagnosed with a mental illness or disorder at some point in their 
lifetime. Depression is the third most common cause of hospitalizations in the United States for 
those aged 18 years-44 years old. For providers who prescribe the use of psychotropic 
medications to treat mental illness, careful consideration needs to be given to rare but serious 
side effects. 
Evidence-Based Practice Model 
Across the educational pavé, numerous evidence-based practice models guide the 
registered nurse and advanced practice registered nurse. For this DNP project, the John Hopkins 
Nursing Evidence-Based Practice Model (JHNEBP) was selected to guide decision-making 
(Dang & Dearholt, 2017). The JHNEBP model is a three-step process that involves a cross-
examination in clinical practice, searching for the best scientific evidence, then translating 
evidence into current practice in order to improve patient care. 
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Evidenced-Based Solutions 
Review of the literature was performed using the following search engines: CINAHL, 
Cochrane, Evidence-Based Medical Reviews, Google Scholar, PsycARTICLES, PsychINFO, 
and PubMed. Keywords utilized during initial and later searches were psychotropic medications, 
psychiatric medications, QT prolongation, QTc prolongation, drug-induced QT interval 
prolongation, 12-lead ECG, ED, ventricular dysrhythmia, polymorphic ventricular 
tachyarrhythmia, Torsades de Pointes, sudden cardiac death, first generation 
antipsychotics/antidepressants, second generation antipsychotics/antidepressants, psychiatric 
diagnosis, mental health in EDs. This search yielded 93 articles from the last 8 years. To narrow 
the search further, Medical Subject Headings (MeSH) terminology that were used included 
psychotropic medications, polymorphic ventricular tachyarrhythmia, ED, prolonged QTc, and 
12-lead ECG, which yielded 51 results. These searches were performed multiple times between 
January 2020 and January 2021. A total of 22 articles were critically appraised to evaluate the 
proposed intervention for this manuscript. The articles were selected based on their quality, 
relevance to their population, and English language.  
Purpose of the EBP Project 
The purpose of this Doctor of Nursing (DNP) project was to (a) conduct an evidence-
based meta-analysis and literature reviews concerning QTc-prolongation due to psychotropic 
medications, (b) recommend the performance of 12-lead ECGs on persons diagnosed with a 
psychiatric disorder between the ages of 18 years and 65 years of age, and (c) evaluate the 
outcomes for patients meeting the recommended guidelines. This project’s intent was to educate 
emergency physicians and nurses to obtain 12-lead ECGs on patients prescribed psychiatric 
medications and to analyze the QT and QTc prolongations due to risk factors.  
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Project Site 
 This project was conducted in an ED located in Southern California. The hospital did not 
have a standardized protocol for patients taking psychotropic medications. Annually, the ED 
admitted 560 adult patients (18 years-65 years of age) who were evaluated for a psychiatric 
disorder, including suicidal ideations, attempts, self-harm, overdose, and assaults. 
Project Implementation Timeline 
Development started January 2020 with the research Clinical Mentor to define the DNP 
project goals of analyzing and assessing QTc prolongation in patients currently prescribed with 
psychotropic medications. A literature review was done to obtain the most recent meta-analyses 
of evidence-based research on psychiatric medications with current FDA concerns for QT/QTc 
prolongations. The ED Physicians supported this DNP project with full collaboration as each 
psychiatric patient on psychotropic medications was seen, assessed, and evaluated for QTc 
prolongation.  
Barriers to this project included the delayed from midyear to the end of the year 2020 
attributable to the SARS-CoV-2 global pandemic and all of its uncertainties. One form of 
resistance the ED/Trauma director faced was the unforeseen pandemonium that devastated the 
country at a startling rate, paralyzing the project’s start. Once stability was achieved, all 
stakeholders agreed to pursue the project in earnest. In the meantime, an education plan and 
protol were developed. To monitor the outcomes of patients seen in the ED who fulfilled criteria, 
a data plan was devised.  
Education Plan/Protocol 
If a patient presented to the ED and acknowledged taking a psychotropic medication, the 
12-lead ECG was ordered to assess for prolonged QTc or abnormal arrhythmia. If positive, the 
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ED physician or registered nurse educated the patient and/or family members or contacted the 
psychiatrist or primary care provider. 
Data Plan/Design 
An Excel spreadsheet was created including age, sex, psychiatric diagnosis, psychotropic 
medication(s), QTc measured in milliseconds (ms), and cardiac rhythm.  
Updated literature reviews were conducted in late 2020 while awaiting IRB review and 
permission to proceed was obtained in January 2021. The progress of the project is outlined in 
Table 1. 
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Table 1  
Project Development and Implementation Timeline 
Intervention/Activities Persons Involved Timeline 
Engaged mentorship of Dr. Kelsoe at 
University of California, of San 
Diego Psychiatry and he was 
amenable 
DNP Student 
Dr. John Kelsoe, MD 
December 12, 2019 
Proposal of DNP Practice project to 
Inland Valley Medical Center 
Emergency Department  
DNP Student 
Jennifer Lee, MSN, RN 
January 10, 2020 
Clinical Stakeholders Presentation 
scheduled to present DNP Practice 
project 
DNP Student 
Jennifer Lee, MSN, RN. 
ED Directors 
ED Physicians 
March 30, 2020 
SARS-COV-2 Global Pandemic 
postponement 
DNP Student 
Jennifer Lee, MSN, RN 
ED Directors 
ED Physicians 
March 19, 2020 
University of California, San Diego 
IRB acceptance letter 
DNP Student 
Dr. John Kelsoe, MD 
September 25, 2020 
Inland Valley Medical Center ED 
IRB acceptance letter  
DNP Student 
Dr. Craig Owens, MD 
January 13, 2021 
University of San Diego IRB 
acceptance letter 
DNP Student 
Michael Terry, DNP, PMHNP, FNP 
Joseph Burkard, DNSc, CRNA 
January 13, 2021 
Dissemination of final results at 
clinical stakeholder presentation 
DNP Student 
Jennifer Lee, MSN, RN 
ED Directors 
ED Physicians 
March 1, 2021 
Final dissemination of final 
manuscript and poster presentation at 
the University of San Diego 
DNP Student 
USD Hahn School of Graduate 
Nursing 
March 4, 2021 
Graduate 
DNP Student 
USD Hahn School of Graduate 
Nursing 
May 22, 2021 
 
 
Project Impact and Cost Benefit Analysis 
 The average cost for a 12-lead ECG in an ED setting in the United States was estimated 
between $50 - $150. The ED where this DNP project was performed charged $150 per 12-lead 
ECG. In 2017, mental and substance use disorder (MSUD) ED visits had service delivery costs 
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of more than $5.6 billion; more than 7% percent of total ED-visit costs ($76.3 billion). 
According to Karaca and Moore (2020), the average cost was $1,500 per ED visit across the 10.7 
million MSUD ED visits, similar to the $3,000 average cost for all 144.8 million ED visits.  
The rate of ED visits for mental health and substance use diagnoses increased 44.1% 
from 2006 to 2014, to a rate of 20.3 visits per 1,000 population (Karaca & Moore, 2020). 
According to the most recent census, the population in Riverside County in 2019 was 2,470,546 
people (U.S. Census Bureau, 2020). At this size, it can be estimated that an average of 50,152 
ED visits were for psychiatric diagnoses. Additionally, up to 27% of ED visits in the United 
States could be managed in the lower-cost setting of physician offices, clinics, and urgent care 
centers (Weinick et al, 2016). If a 12-lead ECG was performed during a psychiatric patient’s 
visit to the ED, patients with prolonged QTc could as the result of medication be identified, 
preventing ED visits and managed by physician offices, clinics, and urgent care centers.  
 As stated above, the average cost of a 12-lead ECG at this DNP project’s ED is $150. 
With 50,152 psychiatric ED visits per year, the total costs for all visits is $75,228,000. If a 12-
lead ECG was running for each visit, it would cost $7,522,800. If 27% of ED visits could be 
regulated by physician offices, clinics, and urgent care centers, it would prevent 13,541 yearly 
visits to the ED. By reducing these visits, it would save $20,311,560 in emergency visit costs 
yielding a total cost avoidance to the ED of $67,705,200. These costs do not include the human 
cost of deadly arrhythmias, including TdP and sudden cardiac death. 
Project Outcome Goals 
 Both short- and long-term goals were benchmarked for this project. Short-term goals 
were constantly re-evaluated throughout the first 4 weeks after the initiation of the clinical 
practice portion of the project. Consecutive assessments were discussed with the ED outcome 
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stakeholders. Short-term goals included determining selective psychiatric patients aged 18 years-
65 years of age, those with one or more psychiatric diagnosis, and those currently prescribed and 
taking psychotropic medications when admitted into the ED. Once confirmation was positive in 
all categories, a 12-lead ECG was performed within the first 30 minutes and presented to the ED 
physician for reading and assessment of QT/QTc prolongation. 
 Long-term goals were evaluated 6 weeks following initiation of the clinical practice 
project and completed February 24, 2021. Long-term goals included establishing the current 
guidelines and recommendations from the FDA, the American Heart Association (AHA), and the 
American College of Cardiology Foundation (ACCF) for a QTc prolongation > 500 ms. If a 
patient met that criteria, the patient would be educated and contact would be made with their 
psychiatric provider. 
Process Indicator Data Monitoring 
 The first process indicators used to translate this current evidence into practice took the 
form of education workshops for ED staff on the rationale and importance of detecting a 
prolongated QT/QTc of those at moderate and high risk. The impact of patient/family and ED 
staff education on psychotropic medications was the focus of this evidence-based project. 
Essential follow up consisted of viewing identified patient data. Obtaining ED staff feedback was 
important to maintain best practice and retention of daily goals. Bi-weekly in-person meetings 
with staff were maintained in order to be attentive to their concerns, questions, observations, and 
commentary.  
Outcome Indicator Data Monitoring 
 The outcome indicator used to translate this current evidence into clinical practice was 
evaluating the number of patients aged 18 years–65 years of age with one or more psychiatric 
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diagnoses and taking one or more psychotropic medications. An average number of 10 patients 
per week are admitted into the ED for drug or alcohol-induced overdose, suicidal ideation or 
suicide attempt, self-harming behaviors, or brought in by law enforcement under California’s 
Welfare and Institution Code 5150 for detention of a mentally disordered persons for evaluation. 
Outcome data were collected biweekly.  
Results 
Results were analyzed for process and outcome indicator data by assessing the average 
number of weekly patients meeting the specific criteria for a total of 50 patients. While this 
project primarily focused on medication statistics, the traits related to gender and age were 
deemed important to capture. The conclusions resulted from calculations and graphing in Excel.  
Psychiatric medications were considered for their potential to cause prolongation of the 
QT/QTc interval and sudden cardiac death; those not meeting this stipulation were not included. 
The seven SGADs and nine SGAPs) were examined (AZCERT, 2013). The cardiac rhythm on 
the ECG was analyzed and documented as displaying sinus bradycardia (n7), regular sinus 
rhythm (n17), sinus tachycardia (n24), atrial fibrillation with rapid ventricular response (n1), or 
regular sinus rhythm with sinus arrythmia (n1). Table 2 displays the raw data collected on Day 1 
of admission to the ED. 
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For most of the sample, their QT and QTc measurements had largely parallel trendlines. 
The space between each trendlines averaged to be 70.5ms; the difference between the QTc 
average of 414.28ms and the QT average of 343.78ms (Figure 1).  
Figure 1 
QT and QTc Measurements for All Patients 
 
The ages of the patients ranged from 18 years-65 years of age. There did not appear to be 
any relationship between age and QTc measurements based on the distribution (Figure 2). The 
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Figure 2 
QTC Measurements by Age  
 
Of the 50 patients, 23 were female and 27 were male. When compared, females had a 
slightly longer average QTc (420.70 ms) compared to the males (408.81 ms); however, current 
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Figure 3 
Average QTc Based on Gender  
 
This introduces the first limitation to the modest data pool, for as previously stated, males 
genetically have longer baseline QTc measurements than females. If this project were repeated or 
expanded, a more robust sample might reveal true differences between the prolongations of 
males and females. By analyzing each gender separately, the project’s findings would likely be 
explained by pre-existing differences. Males and females appeared to have similar numbers in 
the 350-399ms range, but male patients were more likely to be in the 400-449ms range. 
Figure 4 
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Figure 5 
QTc Distribution Among Female Patients 
 
The exact capture of patient diagnoses in relation to their potential for cardiac conduction 
abnormalities did not have a significant role on the relationships between psychotropic 
medications and the patient population’s QTc measurements. Data were collected in an ED 
setting and therefore the noting of cardiac rhythms and various diagnoses are standard when 
performing an EKG.  
The psychotropic medications were grouped into two categories: second-generation 
antipsychotics and second-generation antidepressants. The antipsychotic medications considered 
were Risperidone (dopamine, serotonin, norepinephrine receptor antagonist [DSN-
RAn]/serotonin-dopamine antagonist), Quetiapine (dopamine, serotonin multimodal [DS-MM], 
serotonin-dopamine antagonist), Thioridazine (dopamine and serotonin receptor 
antagonist/dopamine 2 antagonist), and Haldol (dopamine receptor antagonist [D-
RAn]/dopamine 2 antagonist). The second-generation antidepressants noted were Citalopram 
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Escitalopram 
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Fluoxetine 




350-399 (ms) 400-449 (ms) 450-500 (ms)
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(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), Paroxetine 
(serotonin reuptake inhibitor [S-RI]/selective serotonin reuptake inhibitor [SSRI]), and 
Venlafaxine (serotonin and norepinephrine reuptake inhibitor [SN-RI]/dual serotonin and 
norepinephrine reuptake inhibitor [SNRI]). While more than half of the sample was prescribed 
more than one medication, 18 patients were taking one medication; 15 of those were taking a 
sole antidepressant. No patient taking a medication of interest was exclusively on an 
antipsychotic. The graph below displays the three patients with a corresponding drop from 18- to 
15- (gray bars) in order to maintain the attention on the medications of focus. The highest QTc 
measurements were taking Citalopram (489ms) and Fluoxetine (467ms). The lowest QTc 
measurement came from one patient taking Risperidone (365ms). As expected, Citalopram has 
been identified as the antidepressant with the most profound effect for increasing QTc. The 
Fluoxetine patient was 41 years of age; an ideal patient to be monitored in primary care yearly. 
The patient on Risperidone was one of the youngest at age 18 years. Risperidone is one of the 
nine second generation antipsychotics on the list for prolonged QTc measurements. Neither of 
the two patients on Risperidone had high QTc measurements. These findings cannot be 
generalized due to the small sample size.  
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Figure 6 
QTc Measurements Taken for Patients Taking a Single Medication 
 
The intention of this project was rule out QTc prolongation with each medication; 
however, most patients were on two or more medications. For side-by-side comparisons, those 
on more than one medication appear multiple times; therefore, the number of patients 
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When examining the SGADs, Sertraline had the shortest average QTc length at 381ms. 
Of the second-generation antidepressant medications, Sertraline is considered one of the safer 
psychiatric medications. 
Figure 7 
QTc Measurements for Sertraline 
 
Citalopram had the longest average QTc length at 445.33ms and was the longest average 
QTc length of all the medications of focus for this project.  
Figure 8 































PSYCHOTROPIC DRUGS AND QTc IN THE ED  23 
With the exception of Escitalopram, Citalopram appeared to have the longest QTc 
lengths; however, QTc length with Escitalopram were nearly as long at 431.56ms, followed by 
Quetiapine and Fluoxetine with average lengths of 431ms and 430.75, respectively.  
Figure 9 
QTc Measurements for Escitalopram 
 
Figure 10 
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Figure 11 
QTc Measurements for Fluoxetine 
 
 
This EBP project’s limited data might suggest that Escitalopram is riskier when 
compared to Citalopram, which contrasts with published data. Larger EBP projects or formal 
research studies with an adequately powered sample size would likely confirm what is known in 
the literature.  
Three of the 50 patients were on Citalopram; however, nine of the patients are taking 
Escitalopram. Conceivably, the small number of patients taking Citalopram have skewed the data 
for patients taking Citalopram. The average QTc length for Quetiapine should have been on the 
higher end of the spectrum but was not in this limited sample. Furthermore, Fluoxetine’s 
resultant trailing of Quetiapine’s results was consistent with published data reflecting slightly 
lower QTc elongations. 
Escitalopram was the most common of the focus medications (N = 9). This particular 
drug is a commonly prescribed psychotropic medication. The second most common focus 
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Risperidone is a common SGAP. Compared to the other psychotropic medications, the average 
QTc for Risperidone was in the lower range at 385.29ms. 
Figure 12 
QTc Measurements for Thioridazine 
 
The antipsychotic medication Thioridazine ha the shortest average QTc elongation in this 
project at 368ms. When given in the appropriate dose, Thioridazine should not cause any 
lengthening of the QTc. As only one patient is taking Thioridazine, the assumption is that this 
patient was on a proper dose. 
The three remaining medications (i.e., Paroxetine, Haldol, Venlafaxine) revealed QTc 
lengths in the middle range of all observations.  
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Figure 13 
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Figure 15 
QTc Measurements for Venlafaxine 
 
As these three medications are not on the low end of the spectrum, caution should be 
taken when prescribing and their potential effect on QTc should not be discounted. 
In summary, the 10 medications examined in this EBP project included four 
antipsychotic medications and six antidepressant medications. Altogether, their for average QTc 
prolongations from least to greatest were: Thioridazine, Sertraline, Risperidone, Paroxetine, 
Haldol, Venlafaxine, Fluoxetine, Quetiapine, Escitalopram, and Citalopram (Figure 16). Both 
antipsychotic and antidepressant medications were dispersed throughout the sample and the 
range of QTc lengths was 77.33ms (Range: Citalopram = 445.33ms, Thioridazine = 368ms). 
Therefore, this small group were not likely to be reaching alarming QTc levels. Furthermore, the 
spectrum of QTc levels for all the individuals was between the mid 300s to the mid 400s; 
acceptable QTc levels. This group provided the spectrum of ages (18 years-65 years of age) with 
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Figure 16 
Average QTc Based on Medication 
 
Discussion and Sustainability 
 The implementation of this EBP project improved ED staff knowledge on the importance 
of assessing and the analyzing the effects of second-generation antipsychotics and 
antidepressants for rare cases where the QTc interval is greater than 500 ms. Many psychotropic 
medications can delay cardiac repolarization thereby producing prolonged QTc and raising the 
possibility of life-threatening progression to TdP, ventricular fibrillation, or sudden cardiac 
death.  
Barriers impeded successful implementation of this project: 
1. In a high-volume ED, physicians did not consistently order the 12-lead ECG.  
2. Patients might not have been forthcoming with their psychotropic medications or 
neglected to report them thinking they were unrelated to their chief complaint.  























PSYCHOTROPIC DRUGS AND QTc IN THE ED  29 
4. Lack of follow up or perceived risk of litigation for neglecting to interpret an ECG 
not ordered by the physician could have complicated data collection.  
5. Patients perceived as violent and non-compliant might not be able to undergo an 
ECG, even if they were undergoing a cardiac event.  
6. With the time constraints of a busy ED, provider and staff perception of the need for 
the education department could have affected compliance. 
To sustain this project, another DNP student at the University of San Diego Hahn School 
of Nursing could adopt this as their own EBP project. That student would need an emergency 
medicine background, be familiar with cardiac rhythms and ECG interpretation, and possess an 
understanding of the neurochemistry underlying psychotropic medications. As an alternative, an 
ED-based project champion could maintain the project and conduct education sessions for new 
ED staff.  
Implications for Practice 
 Healthy People 2030 included mental health with 15 baseline objectives focused on the 
prevention, screening, assessment, and treatment of mental disorders and behavioral conditions 
(Office of Disease Prevention and Health Promotion, n.d.). While the needed attention given to 
mental health concerns in the United States continues to grow, specialty providers must also 
consider the cardiac health implications of their psychiatric patients. The ED’s role is pivotal in 
the assessment of psychiatric patients that may have an undiagnosed QT/QTc prolongation 
attributed to their psychotropic medications. 
Conclusion 
Advanced practice nurses are positioned to understand the complexity of mental health 
care and emergency medicine. This EBP project supported existing evidence, but the findings 
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from a small patient sample are not generalizable. Continued sustainability of this project would 
yield a larger sample over time to understand the characteristics of each of these medications in 
the local population of ED patients. Goals of this project were to raise awareness in ED providers 
to evaluate QTc measurements of their patients on psychotropic medications and to standardize 
the use of 12-lead ECGs as part of the intake process.  
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